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Abstract
Mutations  in  the  SCN5A  gene  are  responsible  for  multiple  phenotypical  presentations 
including Brugada syndrome, long QT syndrome, progressive familial heart block, sick sinus 
syndrome,  dilated cardiomyopathy,  lone atrial  fibrillation and multiple  overlap syndromes. 
These different phenotypic expressions of a mutation in a single gene can be explained by 
variable  expression  and  reduced  penetrance.  One  of  the  possible  explanations  of  these 
phenomena  is  the  co-inheritance  of  genetic  variants.  We  describe  a  family  where  the 
individuals  exhibit  a  compound  heterozygosity  in  the  SCN5A gene  including  a  mutation 
(R1632H) and a new variant (M858L). Individuals with both the mutation and new variant 
present with a more severe phenotype including spontaneous atrial tachyarrhythmia at young 
age. We give an overview of the different phenotypes of "SCN5A disease" and discuss the 
importance of co-inherited genetic variants in the expression of SCN5A disease.
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Introduction
The α-subunit of the cardiac sodium channel is called Nav1.5 and is encoded by the SCN5A 
gene. Mutations in this gene are known to cause different cardiac abnormalities including the 
channelopathies  Brugada  syndrome  (BrS)  and  long  QT  syndrome  (LQTS),  but  also 
progressive familial heart block (PFHB), sick sinus syndrome (SSS) and more recently dilated 
cardiomyopathy (DCM) and lone atrial fibrillation (l-AF) [1-6]. Overlap syndromes have been 
described involving clinical symptoms or arrhythmias of various arrhythmogenic presentations 
[7].  The  genetic  phenomena  of  reduced  penetrance  and  variable  expression  typical  of 
monogenic  disorders  also  occur  in  the  primary  cardiac  arrhythmia  syndromes  [8].  The 
penetrance of a disease-causing mutation is defined as the proportion of individuals with the 
same  primary  genetic  defect  who  exhibit  the  associated  clinical  symptoms.  Variable 
expression on the other hand is defined as the variation in clinical features (type and severity) 
among carriers of the same genetic defect, even within the same family.Different explanations 
for  reduced  penetrance  and  variable  expression  have  been  proposed:  the  presence  of 
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exogenous factors (electrolyte disturbances, drugs, hormones and body temperature), different 
sodium channel kinetics, haplo-insufficiency and co-inherited genetic variants [9]. Recently 
there has been more interest  in these co-inherited genetic variants such as genes encoding 
regulatory proteins but also genetic  variations in SCN5A itself.  Genetic  variation between 
individuals  is  caused  by  structural  variation  (eg.  Translocations,  inversions  and  splice 
variants), epigenetic variation (eg. methylation of cytosines) and DNA sequence variation, the 
latter  being  the  most  important  factor.  One  type  of  DNA  sequence  variation  is  the 
replacement of one nucleotide by another and this is called a single nucleotide polymorphism 
(SNP). An allele is defined as a genetic locus where more than one genetic sequence has been 
described.  An allele  is called a polymorphism if it's  frequency exceeds 1% in the general 
population; it is called a variant if the frequency is lower than 1%. However, the terminology 
mutation, variant and polymorphism are used on the level of the gene, as well as on the level 
of the phenotype. A mutation often has a negative connotation: they are true disease causing 
mutations. In contrast a neutral polymorphism or variant is a genetic sequence variation with 
no effect on the phenotype (e.g. a silent mutation). Certain polymorphisms or variants cause a 
change in gene function, but their effect on the phenotype is only visible in combination with 
other genetic or environmental factors. This last group is called functional polymorphisms. 
Mutations and neutral polymorphisms can thus be regarded as 2 extremes of a broad spectrum. 
In this article we describe a family with a mutation in SCN5A and a new variant in SCN5A 
not described in literature before. Individuals with the combination of the mutation and the 
variant  in  this  family  present  with  a  more  severe  phenotype  including  spontaneous  atrial 
tachyarrhythmia  during  childhood.                                     
Case  (Table  1)                                            
Index  patient  (Sibling  3)                                                     
A 14-year old girl (sibling 3) presented to our institution with fast palpitations during exercise 
lasting a couple of minutes and resulting in pre-syncope, heavy transpiration and retrosternal 
pain.  Her medical  history revealed a short  loss of consciousness at  age 7,  which was not 
further  investigated.  Electrocardiogram  (ECG)  showed  type  1  atrial  flutter  with  variable 
conduction (3-4/1)  (Figure 1A).  Successful electrical  cardioversion was performed.  Holter 
monitoring after cardioversion revealed bradycardia (as low as 30 beats per minute (BPM)) 
and multiple sinus pauses up to 4.4 seconds. There was also an obvious sinus node arrhythmia 
(Figure 1B). Underlying structural defects were ruled out by transthoracic echocardiogram 
(TTE)  and  magnetic  resonance  imaging  (MRI)  of  the  heart.  Screening  for  an  infectious 
(including Borrelia) or auto-immune cause was negative. Family history includes a maternal 
uncle with pacemaker implantation at age 27 because of recurrent syncopes since age 12 due 
to SSS and ultimately 3th degree atrio-ventricular (AV) block suggesting progressive cardiac 
conduction  slowing.  A  dual  chamber  pacemaker  was  implanted  in  the  index  patient  for 
possible familial SSS (tachy-brady). 
Nine months later she presented to the pacemaker consultation because of recurrent exercise 
related presyncope. Interrogation of the pacemaker and ECG revealed relapse of atrial flutter. 
She  successfully  underwent  flutter  ablation  at  the  cavo-tricuspidal  isthmus. 
Electrophysiological study (EPS) revealed a slight prolongation of the his-ventricle conduction 
interval. No other conduction abnormalities were noted, nor could ventricular arrhythmias be 
provoked.  
Because of the familial  history a genetic  examination  was performed.  She appeared to  be 
carrier  of  both  a  mutation  R1632H  and  a  variant  M858L  in  the  SCN5A  gene.  
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Table 1: Summary of the index patient and family
1= symptomatic sinus pauses and sinus bradycardia; 2= syncope with documentation of third degree AV block 
and sinus pauses; 3= ECG after cardioversion; VT: ventricular tachycardia;  VF: Ventricular fibrillation; BrS: 
Brugada syndrome; ILR: implantable loop recorder;  PFHB: progressive familial heart  block; SSS: sick sinus  
syndrome; PM: pacemaker; AFlut: atrial flutter
Probands
Her mother was identified to be the source of the mutation R1632H in SCN5A. She was 
known for multiple  syncopes highly suggestive for vasovagal  syncope.  However,  infusion 
with  ajmaline  unmasked  a  type  1  Brugada  ECG  (Figure  2).  An  EPS  was  performed: 
ventricular arrhythmias could not be induced. She was implanted with an implantable loop 
recorder  (ILR).  Symptomatic  sinuspauses  and sinsusbradycardia  were detected  and a  dual 
chamber pacemaker was implanted. Because of the absence of a spontaneous type 1 ECG, the 
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negative EPS and the fact no ventricular arrhythmia was documented by the ILR we felt there 
was no indication for an ICD. 
Figure 1: ECG of sibling 3; A: at admission atrial flutter with variable conduction 4/1-3/1; B: after cardioversion 
showing sinus bradycardia and arrhythmia. (25mm/s; 10mm/mV)
Figure 2: ECG of mother before (A) and after (B) ajmaline infusion with induction of typical Brugada type 1  
pattern.  (25mm/s;  10mm/mV)                                          
Her father was the carrier of the variant M858L. Familial history for sudden cardiac death or 
arrhythmias was negative. He had a personal medical history of a single syncope in unclear 
circumstances.  Ajmaline  provocation  was  negative.  Because  of  the  syncope  an  EPS  was 
performed. The EPS was negative and a conservative strategy was proposed. Because of one 
recurrence  of  syncope  rather  suggestive  for  vasovagal  syncope  an  event  recorder  was 
implanted.  Until  now  no  arrhythmia  was  documented.                           
Her younger brother (sibling 4) was seen in the emergency room a few months after her first 
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presentation with an atrial  flutter (3/1 conduction) resulting in a ventricular rhythm of 105 
BPM. An exercise test on a treadmill provoked broad QRS tachycardia at 250 BPM after 3 
minutes of exercise because of 1/1 conduction of the atrial flutter with aberration (Figure 3). 
He underwent flutter ablation. After the procedure there was absence of sinus rhythm, atrial 
standstill  and a slow nodal escape rhythm (35 BPM).  The diagnosis of familial sick sinus 
syndrome was withheld. A ventricular stimulation protocol was negative. A DDD-pacemaker 
was  implanted.  Genetic  testing  revealed  identical  genotype  abnormalities  as  found  in  his 
sister: he is also carrier of the R1632H mutation and of the variant M858L in the SCN5A 
gene.
Figure 3: ECG of sibling 4 during exercise test on a treadmill provoking transition to broad QRS tachycardia due 
to 1/1 conduction of atrial flutter with aberration. There is diffuse intraventricular conduction slowing due to the  
SCN5A  mutation  resulting  in  a  tracing  resembling  ventricular  fibrillation.  (25mm/s;  10mm/mV)      
Her  oldest  sister  (sibling  1)  had  a  history  of  recurrent  fainting  with  prodromes  and 
palpitations. Prolonged Holter monitoring showed sinus arrhythmia. After a negative ajmaline 
provocation test and EPS, an ILR was implanted because of the alarming personal and familial 
history.  The ILR revealed third degree atrio-ventricular (AV) block and sinus pauses of more 
than 3 seconds at time of syncope. The ILR was explanted and a dual chamber pacemaker was 
implanted.  She  is  carrier  of  the  mutation  R1632H in  SCN5A.                         
Her other  brother (sibling 2) is  asymptomatic  up until  now. He is  carrier  of the mutation 
R1632H in SCN5A. Ajmaline provocation and EPS were negative; a conservative strategy 
was  taken  and meticulous  follow-up was  proposed.                                   
Discussion
We hypothesize that in this family the combination of both the variant and the mutation in one 
individual  (compound  heterozygosity)  produced  a  more  severe  phenotype  of  SSS,  with 
spontaneous  atrial  tachyarrhythmias  in  childhood.  We  review  cardiac  sodium  channel 
function, the different phenotypes caused by SCN5A mutations and focus on genetic variants 
as a possible explanation for the phenomena of reduced penetrance and variable expression.
Cardiac  sodium  channel  function  and  structure  with  regard  to  R1632H  and  M858L
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Voltage-gated sodium channels are dynamic transmembrane proteins that open and close to 
conduct sodium ions. They contain a pore-forming ion-conducting α-subunit and ancillary β-
subunits and several regulatory proteins [10]. As already stated, the α-subunit protein is called 
Nav1.5 and is encoded by the SCN5A gene. It consists of four domains, each domain consists 
of 6 transmembrane segments. The channel is responsible for the fast upstroke (phase 0) of the 
cardiac action potential. Time-dependent transitions between distinct conformational states of 
the  channel  protein  is  called  gating  and  is  due  to  molecular  movements  in  response  to 
membrane potential  changes (voltage dependent gating) [11].  We can distinguish between 
activation  and inactivation  (fast,  intermediate  and slow).  Inactivation  starts  simultaneously 
with activation, but since inactivation is a slower process there is a transient conduction of 
sodium  ions  during  phase  0  of  the  action  potential.  Simply  put,  mutations  can  cause 
biophysical gain of function, loss of function or both. Gain of function (as seen in LQTS-3) 
gives  rise  to  prolonged  action  potential  duration  and  the  possibility  of  early 
afterdepolarizations that can induce torsades de pointes [12]. The mechanism underlying gain 
of  function  is  a  sustained  sodium  current  (I-sus)  during  the  plateau  phase  of  the  action 
potential caused by fast reopening due to delayed inactivation causing increased late sodium 
current [9]. Loss of function (as seen in BrS, PFHB, and SSS) causes a slower upstroke of 
phase 0 of the action potential. It might occur because of defective trafficking of the mutant α-
subunit, slower recovery from inactivation, hyperpolarizing shift of inactivation, depolarizing 
shift  of  activation  all  generating  reduced  upstroke  velocity  of  the  action  potential  due  to 
reduced  current  density  [9,11,13].                                      
Alternative splicing of SCN5A creates different isoforms of the α subunit.Isoform Nav1.5 is 
the predominant α subunit in the human heart, but four other functional isoforms have been 
described so far (Nav1.5a,c,d and e respectively) [14]. Functional consequences vary from 
unchanged electrophysiological properties to altered kinetics or even nonfunctional channels. 
It was demonstrated that the T1620K  mutation, a mutation known to cause both LQT3 and 
PFHB,can create different functional effects in the background of different splice variants and 
that these splice variants might thus play a role in the genotype-phenotype relationship [15].    
Nav1.5c  is  the  most  commonsplice  variant  in  the  human  heart  and  lacks  a  glutamine  at 
position  1077  [16].  Common  human  polymorphisms  have  different  electrophysiological 
properties  in the background of Nav1.5c compared to Nav1.5 [17].  Nav1.5e is  a neonatal 
isoform which is downregulated after birth which indicates different expression depending on 
age  [14].                                                                     
Amino acid 1632 of Nav1.5 is located in the fourth segment of domain 4. The fourth segment 
of each domain is positively charged and forms the voltage sensor. This voltage sensor is a 
highly  conserved  region.  It  is  not  located  in  a  possible  alternatively  spliced  region.The 
missense  mutation  R1632H  has  been  associated  with  SSS  and  PFHB  [4].  Two  similar 
electrophysiological  studies  on  R1632H  have  been  performed  with  similar  results  [4,18]. 
There are 2 major abnormalities.  First  there is a negative shift  of steady state inactivation 
towards  hyperpolarized  potentials  resulting  in  reduced  channel  availability.  Secondly, 
recovery from inactivation was dramatically decelerated resulting in an inactivated channel at 
physiological  membrane  potentials  and  normal  heart  rates.  Our  report  is  the  first  to  link 
R1632H with  BrS [19,20].  R1632H has  thus  so  far  been linked to  SSS,  PFHB and BrS. 
Whether it is possible to identify loss of function SCN5A mutations that exclusively result in 
one phenotype,  despite  sharing similar  biophysical  properties,  remains  a matter  of  debate.
Amino acid 858 of Nav1.5 is located in the fifth segment of domain 2. It is not located in a 
possible alternatively spliced region. Segment 5 and 6 of each domain form the ion-conducting 
pore of the channel. Mutations in this region have been associated with different phenotypes 
of SCN5A disease. M858L has not yet been described in the literature before. Our hypothesis 
is that this variant is a modifier of the SCN5A-related channelopathy described in this family.
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Phenotypical expression of cardiac sodium channel disease                                   
As already stated, mutations in SCN5A are responsible for several distinct clinical entities. 
The first clinical entity associated with a mutation in SCN5A was LQTS in 1995 [2]. Since 
then, mutations in all domains of SCN5A have been associated with LQTS, BrS [1], PFHB 
[3], SSS [4], DCM [5] and l-AF [6]. Overlap syndromes have also been described [7]. It has 
been suggested not to view SCN5A mutation carrying patients as having multiple separate 
disease  entities,  but  as  suffering  from one disease  designated  'SCN5A syndrome'  [21].    
Brugada  syndrome                                            
The Brugada syndrome was first described and designated as such in 1992 by the brothers 
Pedro and Josep Brugada [22]. Although a similar disease entity was already described in 
1989 by Martini et al. [23]. Originally the Brugada syndrome was diagnosed in subjects with 
high  risk  for  sudden  cardiac  death  due  to  ventricular  tachyarrhythmias  (polymorphic 
ventricular  tachycardia  (pVT)  and  ventricular  fibrillation  (VF)),  accompanied  by  typical 
coved-type ST-segment  elevation in the right precordial  leads V1 to V3. Loss of function 
mutations in SCN5A have been linked with BrS [1]. The incidence of BrS is around 1 in 8000. 
Approximately  20% of BrS patients  have a mutation  in SCN5A and almost  300 different 
mutations in SCN5A have been described [19,20]. Mutations in regulatory proteins and beta 
subunits of the cardiac sodium channel and mutations in other cardiac ion channels, such as 
calcium and  potassium channels  have  also  been  reported  [19].                         
In the report of the second consensus conference on Brugada syndrome the diagnostic criteria 
and therapeutic  considerations  for BrS were updated [24]. According to these new criteria 
Brugada syndrome is definitively diagnosed when a type 1 ST-segment elevation (≥2 mm, 
negative T) is observed in >1 right precordial lead (V1 to V3) in the presence or absence of a 
sodium channel blocking agent, and in conjunction with one of the following: documented 
VF, polymorphic VT, a family history of sudden cardiac death at <45 years old, coved-type 
ECGs  in  family  members,  inducibility  of  VT  with  programmed  electrical  stimulation  or 
syncope. It is interesting to notice neurally mediated syncope is more common in patients with 
BrS, probably due to an impaired balance of the autonomic nervous system [25]. The ECG 
manifestations may be concealed at a particular moment in time. They can be unmasked by 
fever  [26],  vagotonic  agents  [27],  superior  placement  of  the  ECG  electrodes  [28]  and 
administration  of  a  sodium  channel  blocker  [29].  Drug  challenge  with  sodium  channel 
blockers such as ajmaline and flecainide is used in practice to unmask a type 1 ECG.           
Symptomatic  (syncope,  aborted  sudden  cardiac  death,  documented  VT/VF)  BrS  patients 
should get an implantable cardioverter defibrillator (ICD) [24]. Choosing the right therapy is 
much more difficult in asymptomatic BrS. The report of the second consensus conference on 
Brugada syndrome attributed a great value in risk stratification to whether or not VT could be 
induced in EPS [24]. However, two recent multicenter studies have questioned the importance 
of inducibility of VT in EPS [30,31]. Because of these findings and the rate of complications  
(mainly  inadequate  shocks)  in  patients  with  an  ICD,  there  is  increasing  reluctancy  to 
injudicious ICD implantation in BrS. We summarize clinical and ECG parameters associated 
with  a  worse  outcome  in  Table  2.  Signal  averaged  ECG  measurement  to  determine 
fragmented QRS [32] and late potentials [33,34] is a widely available non-invasive test that 
has proven its usefulness in risk stratification. Genetic data might be proposed in the future as 
a new tool for risk stratification, as mutations causing premature truncation of the protein or 
causing inactive proteins seem to produce a more severe phenotype [35]. There are strong 
clinical and experimental data suggesting quinidine could be a good alternative therapy for 
asymptomatic BrS, nevertheless more studies are needed [36].
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Table 2: Predictors of worse outcome in asymptomatic BrS
Progressive  familial  heart  block                                        
According to the 'Online Inheritance In Men' (OMIM) library, PFHB is the correct term for 
the disease formerly known as progressive cardiac conduction defect,  which is also called 
Lev-Lenegre  disease.  Therefore  we  encourage  this  entity  to  be  called  PFHB.  It  is  the 
prevailing phenotype in carriers with loss of function mutations in SCN5A [37]. This defect is 
characterized  by  progressive  alteration  of  impulse  propagation  through  the  His-Purkinje 
system, with right or left bundle branch block and widening of the QRS complex, resulting in 
complete atrio-ventricular block, syncope and sometimes even sudden death. In vitro studies 
have demonstrated that properties of loss of function include reduced density of the sodium 
current  and  altering  of  the  gating  properties  [38,39].  Information  obtained  from a  mouse 
model  shows age-related  channelopathy-mediated  fibrosis  of  the  myocardium [40].  These 
findings  support  the  hypothesis  suspecting  a  fibrotic  process  to  be responsible  for  slowly 
progressive AV block. The first association of SCN5A mutations with PFHB originated from 
the description of a novel mutation causing either PFHB or BrS in the same family [3,41]. 
Because of the age-related progression and the possible severity of the defect, it is advised that 
carriers  of  a  SCN5A mutation  get  a  yearly  clinical  and ECG follow-up  [37].  Pacemaker 
implantation is indicated for advanced second degree and third degree AV block [42].       
Sick  sinus  syndrome                                                 
SSS  comprises  different  forms  of  arrhythmia  that  result  from  sino-atrial  node  and  atrial 
dysfunction. It is diagnosed by ECG and characterized by variable manifestations including 
sinus bradycardia, sinus arrest, atrial standstill,  and tachy-brady syndrome (supraventricular 
tachycardia alternating with episodes of sinus bradycardia)  [43]. In the first  description of 
SCN5A related  SSS,  the  authors  suggested  an  autosomal  recessive  pattern  of  inheritance 
because  SSS was associated  with  compound heterozygous  loss  of  function  mutations,  for 
example R1632H + delF1617 [4]. However this hypothesis was contested a couple years later 
when  a  novel  mutation  was  found  that  resulted  in  an  autosomal  dominant  pattern  of 
inheritance of SSS [44]. Mutations in SCN5A have been demonstrated to impair the coupling 
of electrical events between the pacemaker cells and the cells surrounding them within the 
sino-atrial node, and cause impairment of propagation of electrical activity from the sino-atrial 
node to atrial tissue [45]. Pacemaker implantation is the treatment of choice for symptomatic 
sinus node dysfunction [42]. Tachyarrhythmias should be treated according to the most recent 
guidelines  [46].                                                      
Dilated  cardiomyopathy                                            
Dilated cardiomyopathy (DCM) is a primary myocardial disease characterized by dilatation of 
the left or both ventricles and impaired systolic function, which may proceed to congestive 
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heart failure [47]. Up to 50% of dilated cardiomyopathies are idiopathic and 20 % of these 
display  familial  prevalence  [48].  Mutations  in  genes  encoding  various  proteins  that  are 
involved in the contractile apparatus and cytoskeleton were found in these families [48]. It was 
only  in  2004  that  a  mutation  in  SCN5A  was  linked  with  DCM,  thereby  expanding  the 
spectrum of SCN5A associated diseases [5]. Most of these mutations are found in patients 
who display multiple phenotypes. The biophysical effects of these mutations are often both a 
combination  of  gain  and  loss  of  function  [49].  The  pathophysiology  of  DCM caused  by 
SCN5A  mutations  still  remains  unclear.  There  are  however  two  hypotheses.  Ge  et  al 
speculated that the interactions between cardiac sodium channels and intracellular proteins are 
disrupted, thereby disturbing normal cardiomyocyte structure and function [49]. On the other 
hand it is known that gain of function mutations lead to a higher influx of sodium and an 
increased  intracellular  sodium  concentration  with  a  secondary  increase  in  intracellular 
calcium.  This is  associated  with cellular  remodeling  and development  of  hypertrophy and 
heart  failure  [50].  Therapy  for  SCN5A  associated  DCM  exists  of  standard  therapy  for 
congestive  heart  failure.                                                
Long  QT  syndrome  type  3                                              
Long QT syndrome is an inherited arrhythmogenic disease characterized by prolongation of 
the QT interval, the ECG equivalent of an increased action potential duration in ventricular 
cardiomyocytes  and  thus  delayed  ventricular  repolarization.  The  limit  for  corrected  QT 
interval  as  calculated  by  the  formula  of  Bazett  is  470  milliseconds  for  females  and  450 
milliseconds for males [51]. Prolongation of the QT interval  due to increased late  sodium 
current predisposes to early afterdepolarizations that induce torsades de pointes, which may 
result  in recurrent  syncope or sudden cardiac death [9,12]. Among the numerous different 
genetic subtypes (all encoding a protein that is directly or indirectly involved in repolarization) 
of the syndrome, LQT-3 is caused by gain-of-function mutations in SCN5A. Inherited LQTS 
has an estimated incidence of 1 in 3000 and LQT-3 has a relative prevalence of 10% [52]. So 
far more than 80 different SCN5A mutations have been described [53]. In contrast to the other 
LQTS subtypes, patients with LQT-3 tend to experience cardiac events during sleep and rest 
when the heart rate is slow, rather than during exercise or at times of emotions seen in other 
types  of  LQTS  [54].  Standard  treatment  for  LQT-3  include  potassium  substitution, 
spironolactone  and  ICD  implantation.  Recently  however,  2  drugs  that  target  the 
pathophysiology of LQT-3 have come available. Mexiletine attenuates the increased inward 
sodium current, thereby abbreviating the QT interval [55]. Ruan et al. showed mexiletine has 
mutation specific effects [56]. It can exacerbate QT prolongation in some mutations so caution 
should  be  used  when  recommending  mexiletine  to  carriers  of  mutations  with  undefined 
electrophysiological properties [57]. Ranolazine is a selective blocker of late sodium current 
and abbreviates the QTc interval in a dose dependent manner [58,59]. Although its promising 
properties,  larger  clinical  trials  are  needed  to  confirm  the  efficacy  of  ranolazine.    
Atrial  Fibrillation                                                  
Atrial  fibrillation  in  the  absence  of  risk  factors  (advanced  age,  diabetes  mellitus,  arterial 
hypertension, structural heart disease and congestive heart failure) is a condition known as 
lone  atrial  fibrillation  (l-AF) [60].  Lone AF has  been associated  with  mutations  in  genes 
encoding potassium channels and more recently with mutations in SCN5A [6,61]. Both gain 
and loss of function mutations in SCN5A are linked to l-AF. BrS has been associated with an 
increased risk for AF. Amin et al showed that loss of function SCN5A mutations in BrS are 
associated with intra-atrial conduction slowing, a substrate for AF maintenance, and decreased 
atrial ectopic activity, which may inhibit the trigger for AF initiation [62]. Similar to what is 
observed in LQT-3, gain of function mutations result in increased late sodium current and 
prolongation of the action potential duration thereby triggering early afterdepolarizations, not 
only in ventricular cardiomyocytes but also in atrial cardiomyocytes. Flecainide is the drug of 
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choice  in  AF  caused  by  gain  of  function  SCN5A  mutations  and  in  prevention  of  atrial  
arrhythmias  in  LQT-3  [63,64].                                                 
Early  repolarization  syndrome                                             
Early repolarization is characterized by an elevation of the junction between the end of the 
QRS complex and the beginning of the ST segment  (J point)  from baseline on ECG. For 
decades it has been considered to be a benign ECG manifestation. However, recently it has 
been associated with idiopathic VF and sudden cardiac arrest in a large clinical trial [65]. Up 
until now, one abstract has been published linking SCN5A mutations with early repolarization 
syndrome [66].  The exact  role  of  SCN5A in ERS has  to  be further  investigated.         
Overlap  syndromes                                              
Overlap syndromes have been described; they involve clinical symptoms or arrhythmias of the 
various  presentations  in  one  patient  (BrS,  PFHB,  LQTS,  SSS,  l-AF  and  DCM).  This 
description is also used when a single mutation causes various arrhythmogenic phenotypes in 
different families or members of one family. Because of this overlap, Remme et al. propose to 
call patients who possess an SCN5A mutations as having 'SCN5A syndrome or disease' with 
the different phenotypical expressions as a subtype of this disease [21].                     
It  is  plausible  to  understand overlap exists  between phenotypes  caused by mutations  with 
similar functional abnormalities (loss of function mutations and gain of function mutations 
respectively). Multiple reports have been published [41,63,67-69]. However, overlap between 
LQTS and phenotypes associated with loss of function mutations have also been described 
[7,70,71].  Studies  on  heterologous  expression  systems  have  shown that  one  mutation  can 
exhibit both loss of function and gain of function properties, thereby providing an explanation 
for these at first sight rather strange overlap syndromes [7,71]. Another possible explanation is 
the presence of a specific variant in the background of an alternatively spliced Nav 1.5 protein 
generating  functionally  distinct  channels  [15].  Choice  of  treatment  is  dependent  on  the 
prevailing  clinical  phenotype.                                       
Variable expression, reduced penetrance and the importance of genetic variants          
Co-inherited  genetic  variants  are  a  major  point  of  interest  for  researchers  to  explain  the 
phenomenena of variable expression and reduced penetrance. Genetic modification by genetic 
variants may occur in the disease gene locus itself or in a genetic locus apart from the disease 
gene locus, for example in genes encoding ancillary β-subunits or genes encoding one of the 
several  regulatory  proteins  [8].                                       
The spectrum and prevalence of non-synonymous (inducing a change in amino acid or stop 
codon) genetic variants in the cardiac sodium channel was determined among 829 healthy 
subjects from different ethnicities [72]. Another research group did the same in a Japanese 
population  consisting  of  166  arrhythmic  patients  and  232  healthy  controls  [73].  Variant 
M858L was not found in these studies, and has not been described in literature before.    
Research  on genetic  variants  is  done through clinical  studies  preferably  in  large  families, 
electrophysiological studies (eg. patch-clamp studies on heterologous expression systems) and 
transgenic animal models. Induced pluripotent stem cells (iPS) are a promising new technique. 
Research remains necessary to unravel the role of genetic variants in channel function and 
their  correlation  with  disease.                                     
SNP H558R is the most prevalent and most investigated genetic variant in SCN5A but was not 
found in either of the family members in the case described. Studies have shown that the 
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presence  of  the  less  common allele  G attenuated  the  ECG characteristics  of  the  Brugada 
syndrome among carriers of an SCN5A mutation [74]. There is also evidence for mutation-
specific effects on SCN5A related SSS (the R558 variant caused aggravation of the defect in 
some mutations  and  correction  of  the  defect  in  others)  [75],  stabilization  of  channel  fast 
inactivation in a certain gain-of-function mutation [76] and rescuing defective trafficking of 
the Nav1.5 protein caused by a loss of function mutation [77]. Other variations in the genome 
and  their  effects  on  SCN5A mutations  that  have  been investigated  include  SNP R1193Q 
[17,78,79], splice variant Q1077 [17] and SNP S1103Y [17,80]. All the observations done in 
these studies provide a plausible mechanism for decreased or increased arrhythmogenic events 
in patients who not only carry mutants but also carry specific cardiac sodium channel variants 
that  act  as functional  polymorphisms.  We presume a similar  interaction between mutation 
R1632H and variant M858L in the family we described causing increased arrhythmogenic 
events  (atrial  tachy  arrhythmias)                                        .
Although  co-inherited  genetic  variants  are  extremely  interesting  and  important  in 
understanding reduced penetrance and variable expression, we must also be cautious because 
not  every  genetic  variant  plays  a  role  in  disease  expression.  We  currently  do  not  have 
guidelines  for  determining  from  what  point  on  certain  anomalies  in  electrophysiological 
studies are clinically important. The reliance on statistically significant functional differences, 
certainly when they are subtle, as the sole criterion for claiming that a sequence variant is a 
disease  causing  mutation  has  been  put  into  question  [81].  Sorting  signal  from  noise  as 
postulated by Milan et al is an intriguing challenge [81].                                     
Another  interesting  issue  regarding  SCN5A mutations  is  reduced  penetrance.  Oliva  et  al. 
therefore suggested that it should be avoided seeing a mutation as a certain predictor of sudden 
death, but rather as a risk factor [82]. Probst et al. take it even a step further: in families with a  
known SCN5A mutation  they found 8 individuals  with phenotypical  familial  BrS without 
carrying the familial SCN5A mutation [83]. Therefore they suggested that modulating factors 
within the studied families  (genetic  background) are sufficiently  powerful  to  evoke a BrS 
positive ECG. This genetic background includes all proteins and molecules that play a role in 
the pathophysiology of BrS, or by extension the pathophysiology of all possible phenotypical 
expressions  of  SCN5A  mutations.                                                
Limitations  of  the  study                                                          
We describe a single family where the combination of a known mutation and a new variant 
seems to produce a more severe phenotype than the mutation per se. This aggravation was not 
due  to  age  related  factors  since  the  youngest  siblings  were  those  suffering  from  atrial 
tachyarrhythmia (Table 1). Of course, reduced penetrance and variable expression of R1632H 
in this family can possibly explain the gravity of the phenotype seen in the two children with 
atrial  tachyarrhythmia.  Furthermore  since we did not  perform cellular  electrophysiological 
studies on R1632H or M858L or the combination, we can't prove our hypothesis with absolute 
certainty. More clinical or cellular data concerning M858L are needed to definitely consider 
this variant as a functional or pathogenic polymorphism.                                      
Conclusion
SCN5A mutations  are  prone to  variable  expression and reduced penetrance.  The different 
phenotypes include not only BrS and LQTS, but also PFHB, SSS, l-AF and DCM, each of 
them with a specific risk for sudden cardiac death, treatment and follow-up. Genetic variation 
in the disease-causing gene or in other genes involved in the pathophysiology of the different 
phenotypes  is  one  of  the  most  important  explanations  for  the  phenomena  of  reduced 
penetrance  and variable  expression.                                                    
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We described a family where some individuals possess a combination of a loss of function 
mutation  and  a  variant  in  SCN5A.  In  the  literature  the  mutation  R1632H  was  not  yet 
associated with the BrS phenotype. The variant M858L has not been described in literature 
before. The individuals carrying the mutation and the variant had a more severe phenotype 
including atrial tachyarrhythmia in chidhood in comparison with individuals carrying only the 
mutation.  Since this  variant  has  not  been described in  large  population  studies  of  genetic 
variants  in  the  SCN5A gene and the  specific  phenotypic  findings,  it  seems reasonable  to 
assume that  the M858L variant  might  be a  modifier  in  the SCN5A-related  channelopathy 
described in this family. However further studies are needed to investigate whether M858L is 
a  true  pathogenic  mutation,  a  functional  polymorphism  or  just  a  neutral  polymorphism.
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